StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Who remembers

<< Previous

Bullboard Posts

Next >>

Comment by brad129on Mar 21, 2023 11:47am

64 Views

Post# 35351343

RE:RE:RE:Who remembers

Cut straight from the press release

Approval to issue common shares pursuant to the Capital Commitment Agreement with GEM Global Yield in excess of 25% of the issued and outstanding common shares; and

this shows why GEM may want the price lower, they have approved 25 million dollars, the lower the price the greater percentage of the company they get with each draw. You stated they want 25% of the company? Just shows your comprehension skills the news release states quite clearly in excess of 25%.

let me guess the February 02 2023 is old news shouldn't be brought up now?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China